Dr. Kerri Purdy
Dr. Purdy is an Assistant Professor of Medicine in the Division of Dermatology and Division Head of Dermatology at Dalhousie University in Halifax, Nova Scotia. Dr. Purdy has a full time academic practice in Halifax. After receiving her medical degree, Dr. Purdy completed her residency training in internal medicine, followed by dermatology, at Dalhousie University. Additionally, she has completed fellowship examinations in both specialities. Dr. Purdy has been a member of regional and national advisory boards. She is a past president of the Canadian Dermatology Association
Friday NOV 12, 2021
Taking the Long View in Disease Control in Atopic Dermatitis
Patients with AD truly experience a Multidimension disease Burden. This includes debilitating the burden of signs of AD but also the consequences of AD symptoms on overall Quality of life. Another challenge that AD Patients face is living with the unpredictability of the disease, not knowing when a flare could occur. Episodic management of AD may not address the overall disease burden. AD being a chronic disease, patients suffering from uncontrolled disease can benefit from long term management. This symposium will look at considerations for selecting an AD treatment option for long-term use, all while reviewing most recent Long term and Real World evidence data in the management of moderate to severe atopic dermatitis.
- Understand the current concepts around Long-Term control of atopic dermatitis
- Review considerations for selecting an AD treatment option for long-term use
- Review recent long-term and RWE data for biologic therapy in atopic dermatitis
Saturday NOV 13, 2021
A Sneak Peek at Bimekizumab: A Review of the Data
Dr. Ron Vender and Dr. Kerri Purdy will examine the efficacy and safety of bimekizumab in patients with moderate to severe psoriasis. At the conclusion of this session, physicians will be informed about: bimekizumab's clinical trial efficacy and safety data in patients with moderate to severe psoriasis; and Canadian investigators' first-hand experience with bimekizumab in patients with moderate to severe psoriasis.